Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Lakefront Biotherapeutics - Sponsored ADR (LKFT) vs Vericel Corporation (VCEL)

Lakefront Biotherapeutics - Sponsored ADR and Vericel Corporation are both Biotechnology companies. Lakefront Biotherapeutics - Sponsored ADR and Vericel Corporation are of similar size ($2.0B and $2.0B). Lakefront Biotherapeutics - Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Vericel Corporation trades at 82.6×. Vericel Corporation grew revenue faster over the last twelve months: 23.0% against −52.2%. Vericel Corporation has the higher net margin (7.91% vs −6.81%) and the higher return on invested capital (5.49% vs 0.00%). Across the 20 metrics below, Vericel Corporation leads on 13 and Lakefront Biotherapeutics - Sponsored ADR on 7.

Valuation

Metric LKFT VCEL Biotechnology median
P/E n/m 82.63 7.88
P/S 6.86 6.61 11.47
P/B 0.51 5.47 2.52
Price to free cash flow n/m 32.85 21.16
EV/EBITDA 1.59 62.29 0.74
EV/Sales (2.35) 6.36 10.73
Earnings yield (0.97%) 1.21% (28.84%)
Free cash flow yield (30.82%) 3.04% (23.03%)

Profitability

Metric LKFT VCEL Biotechnology median
Gross margin 89.75% 74.56% 65.16%
Operating margin (90.11%) 5.95% 0.00%
Net margin (6.81%) 7.91% 0.00%
Free cash flow margin 0.00% 20.13% 0.00%
Return on equity 0.00% 7.16% (57.72%)
Return on assets 0.00% 5.16% (49.22%)
Return on invested capital 0.00% 5.49% 0.00%

Growth

Metric LKFT VCEL Biotechnology median
Revenue growth (TTM) (52.22%) 22.95% 5.64%
EPS growth (last fiscal year) 355.37% 60.00% —
Revenue growth, 5-year CAGR 15.75% 17.34% 8.40%
Net income growth, 5-year CAGR 0.00% 41.97% 0.00%

Health

Metric LKFT VCEL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 32.84 5.04 4.73
Net debt to EBITDA (8.53) (6.08) 0.96

Dividend

Metric LKFT VCEL Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric LKFT VCEL Biotechnology median
Market cap 1.99b 2.03b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack